FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012950246> ?p ?o ?g. }

• W3012950246 abstract "Abstract Background The evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status. Methods Participants were 106 individuals with FXS between ages 6 and 23 years who had IQs within the range of intellectual disability (IQ < 70). ELS procedures for collecting samples in conversation and narration were followed and analyzed separately. Five measures were derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers): number of C-units per minute (talkativeness), number of different word roots (vocabulary), C-unit length in morphemes (syntax), percentage of C-units containing dysfluency (utterance planning), and percentage of C-units that were fully or partly unintelligible (articulatory quality). ELS procedures were administered twice at 4-week intervals for each participant. Standardized tests and informant reports were administered and provided measures for evaluating construct validity of ELS measures. Results We found low rates of noncompliance, suggesting the task can be completed meaningfully by most individuals with FXS, although noncompliance was higher for younger, lower IQ, and more autistic participants. Minimal practice effects and strong test-retest reliability over the 4-week interval were observed for the full sample and across the range of ages, IQs, and autism symptom severity. Evidence of convergent construct validity was observed for the measures of vocabulary, syntax, and unintelligibility for the full sample and across the range of IQ and autism symptom severity, but not for participants under age 12. Conversation and narration yielded largely similar results in all analyses. Conclusions The findings suggest that the ELS procedures are feasible and yield measures with adequate psychometric properties for a majority of 6 to 23 years with FXS who have ID. The procedures work equally well regardless of level of ID or degree of ASD severity. The procedures, however, are more challenging and have somewhat less adequate psychometric properties for individuals with FXS under age 12." @default.
• W3012950246 created "2020-03-27" @default.
• W3012950246 creator A5014629170 @default.
• W3012950246 creator A5016953572 @default.
• W3012950246 creator A5025967960 @default.
• W3012950246 creator A5042597779 @default.
• W3012950246 creator A5046083954 @default.
• W3012950246 creator A5062947490 @default.
• W3012950246 creator A5063388569 @default.
• W3012950246 creator A5069689681 @default.
• W3012950246 creator A5073128102 @default.
• W3012950246 creator A5073237077 @default.
• W3012950246 creator A5082404600 @default.
• W3012950246 date "2020-03-24" @default.
• W3012950246 modified "2023-10-15" @default.
• W3012950246 title "Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity" @default.
• W3012950246 cites W1487226252 @default.
• W3012950246 cites W1885358257 @default.
• W3012950246 cites W1968225092 @default.
• W3012950246 cites W1969405240 @default.
• W3012950246 cites W1979516671 @default.
• W3012950246 cites W1998310884 @default.
• W3012950246 cites W1999465661 @default.
• W3012950246 cites W2002682786 @default.
• W3012950246 cites W2007832365 @default.
• W3012950246 cites W2012021311 @default.
• W3012950246 cites W2016248942 @default.
• W3012950246 cites W2017989055 @default.
• W3012950246 cites W2023125723 @default.
• W3012950246 cites W2023404090 @default.
• W3012950246 cites W2025199569 @default.
• W3012950246 cites W2032687048 @default.
• W3012950246 cites W2033379804 @default.
• W3012950246 cites W2039097630 @default.
• W3012950246 cites W2040009554 @default.
• W3012950246 cites W2044352563 @default.
• W3012950246 cites W2056971277 @default.
• W3012950246 cites W2058913581 @default.
• W3012950246 cites W2070233808 @default.
• W3012950246 cites W2073347350 @default.
• W3012950246 cites W2091695556 @default.
• W3012950246 cites W2101716121 @default.
• W3012950246 cites W2103288787 @default.
• W3012950246 cites W2106750209 @default.
• W3012950246 cites W2121994984 @default.
• W3012950246 cites W2122684341 @default.
• W3012950246 cites W2122820712 @default.
• W3012950246 cites W2126115066 @default.
• W3012950246 cites W2128884480 @default.
• W3012950246 cites W2137737640 @default.
• W3012950246 cites W2139909945 @default.
• W3012950246 cites W2142548379 @default.
• W3012950246 cites W2155596242 @default.
• W3012950246 cites W2156668878 @default.
• W3012950246 cites W2167197543 @default.
• W3012950246 cites W2168695429 @default.
• W3012950246 cites W2178954357 @default.
• W3012950246 cites W2237631658 @default.
• W3012950246 cites W2517687243 @default.
• W3012950246 cites W2518541914 @default.
• W3012950246 cites W2589935846 @default.
• W3012950246 cites W2599349091 @default.
• W3012950246 cites W2607787682 @default.
• W3012950246 cites W2609573770 @default.
• W3012950246 cites W2747559513 @default.
• W3012950246 cites W2751709943 @default.
• W3012950246 cites W2759433538 @default.
• W3012950246 cites W2759531769 @default.
• W3012950246 cites W2772067948 @default.
• W3012950246 cites W2774363489 @default.
• W3012950246 cites W2807525941 @default.
• W3012950246 cites W2890742831 @default.
• W3012950246 cites W2904556124 @default.
• W3012950246 cites W2925324830 @default.
• W3012950246 cites W2972397981 @default.
• W3012950246 cites W2973215469 @default.
• W3012950246 cites W3003097009 @default.
• W3012950246 cites W3016332336 @default.
• W3012950246 doi "https://doi.org/10.1186/s11689-020-09313-6" @default.
• W3012950246 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7119274" @default.
• W3012950246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32241250" @default.
• W3012950246 hasPublicationYear "2020" @default.
• W3012950246 type Work @default.
• W3012950246 sameAs 3012950246 @default.
• W3012950246 citedByCount "32" @default.
• W3012950246 countsByYear W30129502462020 @default.
• W3012950246 countsByYear W30129502462021 @default.
• W3012950246 countsByYear W30129502462022 @default.
• W3012950246 countsByYear W30129502462023 @default.
• W3012950246 crossrefType "journal-article" @default.
• W3012950246 hasAuthorship W3012950246A5014629170 @default.
• W3012950246 hasAuthorship W3012950246A5016953572 @default.
• W3012950246 hasAuthorship W3012950246A5025967960 @default.
• W3012950246 hasAuthorship W3012950246A5042597779 @default.
• W3012950246 hasAuthorship W3012950246A5046083954 @default.
• W3012950246 hasAuthorship W3012950246A5062947490 @default.
• W3012950246 hasAuthorship W3012950246A5063388569 @default.
• W3012950246 hasAuthorship W3012950246A5069689681 @default.
• W3012950246 hasAuthorship W3012950246A5073128102 @default.
• W3012950246 hasAuthorship W3012950246A5073237077 @default.

• next